[
  {
    "ts": null,
    "headline": "AbbVie to Buy Experimental Depression Drug From Gilgamesh For up to $1.2 Billion",
    "summary": "AbbVie (ABBV) will acquire Gilgamesh Pharmaceuticals' investigational depression drug for up to $1.2",
    "url": "https://finnhub.io/api/news?id=86556f759a8e2969ec1ae65cb8efec7cd993e9283e297aa639eb58771c1279c9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756143067,
      "headline": "AbbVie to Buy Experimental Depression Drug From Gilgamesh For up to $1.2 Billion",
      "id": 136522409,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) will acquire Gilgamesh Pharmaceuticals' investigational depression drug for up to $1.2",
      "url": "https://finnhub.io/api/news?id=86556f759a8e2969ec1ae65cb8efec7cd993e9283e297aa639eb58771c1279c9"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Monday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=c3be45a48032271aec1e601c2a047cf4c6ed2f885e087e0c2824a9c7f17c6f2c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756139460,
      "headline": "AbbVie Inc. stock underperforms Monday when compared to competitors",
      "id": 136528091,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=c3be45a48032271aec1e601c2a047cf4c6ed2f885e087e0c2824a9c7f17c6f2c"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Keurig Dr Pepper Acquires JDE Peet's in $18.37 Billion Deal; Musk Reportedly Sues Apple, OpenAI",
    "summary": "The Dow Jones and the S&P 500 stock indexes were down, while the Nasdaq Composite was up in late-mor",
    "url": "https://finnhub.io/api/news?id=220b13490ee2f1ec9a2b980e8739cfac36be5d2ef8c70d8db523cd9d4c8b0590",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756136265,
      "headline": "Top Midday Stories: Keurig Dr Pepper Acquires JDE Peet's in $18.37 Billion Deal; Musk Reportedly Sues Apple, OpenAI",
      "id": 136509249,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The Dow Jones and the S&P 500 stock indexes were down, while the Nasdaq Composite was up in late-mor",
      "url": "https://finnhub.io/api/news?id=220b13490ee2f1ec9a2b980e8739cfac36be5d2ef8c70d8db523cd9d4c8b0590"
    }
  },
  {
    "ts": null,
    "headline": "US Rheumatologists Point to Difficult-to-Treat populations, Oral Delivery, and Novel Mechanisms as the Key Drivers of Future RA Treatment Evolution, According to Spherix Global Insights",
    "summary": "TNF biosimilars continue to expand, underscoring the tension between payer-driven cost pressures and pipeline-driven opportunity.EXTON, PA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- According to the latest findings from Spherix Global Insights’ Market Dynamix™: Rheumatoid Arthritis (US) 2025, the most notable near-term disruption in the RA market stems from continued TNF biosimilar adoption at the expense of branded biologics, namely AbbVie’s Humira. The analysis, based on an online survey of 104 rheuma",
    "url": "https://finnhub.io/api/news?id=b6c540e9c20d8d1856d40d9dafb4fc68f6e637f031577691671816b7a64b776f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756131240,
      "headline": "US Rheumatologists Point to Difficult-to-Treat populations, Oral Delivery, and Novel Mechanisms as the Key Drivers of Future RA Treatment Evolution, According to Spherix Global Insights",
      "id": 136507966,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "TNF biosimilars continue to expand, underscoring the tension between payer-driven cost pressures and pipeline-driven opportunity.EXTON, PA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- According to the latest findings from Spherix Global Insights’ Market Dynamix™: Rheumatoid Arthritis (US) 2025, the most notable near-term disruption in the RA market stems from continued TNF biosimilar adoption at the expense of branded biologics, namely AbbVie’s Humira. The analysis, based on an online survey of 104 rheuma",
      "url": "https://finnhub.io/api/news?id=b6c540e9c20d8d1856d40d9dafb4fc68f6e637f031577691671816b7a64b776f"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline",
    "summary": "AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals Inc. (\"Gilgamesh\") today announced a definitive agreement under which AbbVie will acquire Gilgamesh's lead investigational candidate, currently in clinical development for the treatment of patients with moderate-to-severe major depressive disorder (MDD).",
    "url": "https://finnhub.io/api/news?id=3dd825a71a906a83a1d9ce92d5b4216ef67b2d6e6917503931adca8ebfadd117",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756126740,
      "headline": "AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline",
      "id": 136507968,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals Inc. (\"Gilgamesh\") today announced a definitive agreement under which AbbVie will acquire Gilgamesh's lead investigational candidate, currently in clinical development for the treatment of patients with moderate-to-severe major depressive disorder (MDD).",
      "url": "https://finnhub.io/api/news?id=3dd825a71a906a83a1d9ce92d5b4216ef67b2d6e6917503931adca8ebfadd117"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie wagers more than $1B on Gilgamesh’s psychedelic drug",
    "summary": "The asset deal thrusts AbbVie to the forefront of the psychedelic field, handing it a therapy that recently scored positive Phase 2 results in major depression.",
    "url": "https://finnhub.io/api/news?id=3483d981362ac6a54ff016b236db9a8061811a3a8a2134576b0481aefcaa977f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756122600,
      "headline": "AbbVie wagers more than $1B on Gilgamesh’s psychedelic drug",
      "id": 136522411,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The asset deal thrusts AbbVie to the forefront of the psychedelic field, handing it a therapy that recently scored positive Phase 2 results in major depression.",
      "url": "https://finnhub.io/api/news?id=3483d981362ac6a54ff016b236db9a8061811a3a8a2134576b0481aefcaa977f"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV): Evaluating Valuation as Rinvoq Achieves Phase 3 Success in Severe Alopecia Areata",
    "summary": "AbbVie (ABBV) just released encouraging news for investors considering their next move. The company announced positive topline results from late-stage studies of upadacitinib (Rinvoq) as a treatment for severe alopecia areata, achieving both primary and secondary endpoints with significant improvements in hair regrowth. With a favorable safety profile also reported, AbbVie is preparing Rinvoq for potential regulatory submission in another indication. This development further strengthens its...",
    "url": "https://finnhub.io/api/news?id=481c1ab3a782cdb73605c684473083e62a6ef33e514dd41eaacfbe78585a9fe8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756117410,
      "headline": "AbbVie (ABBV): Evaluating Valuation as Rinvoq Achieves Phase 3 Success in Severe Alopecia Areata",
      "id": 136507969,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) just released encouraging news for investors considering their next move. The company announced positive topline results from late-stage studies of upadacitinib (Rinvoq) as a treatment for severe alopecia areata, achieving both primary and secondary endpoints with significant improvements in hair regrowth. With a favorable safety profile also reported, AbbVie is preparing Rinvoq for potential regulatory submission in another indication. This development further strengthens its...",
      "url": "https://finnhub.io/api/news?id=481c1ab3a782cdb73605c684473083e62a6ef33e514dd41eaacfbe78585a9fe8"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Is A Top Biotech Pick",
    "summary": "Q2 earnings results were strong for AbbVie as top line growth is at a historically high level and operating margin expanded due to SG&A efficiencies.",
    "url": "https://finnhub.io/api/news?id=9036234003410c3dec310b1f6658396f9ccbd1362cb640fa63a2fc566734f6e5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756113486,
      "headline": "AbbVie Is A Top Biotech Pick",
      "id": 136507713,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175801616/image_2175801616.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Q2 earnings results were strong for AbbVie as top line growth is at a historically high level and operating margin expanded due to SG&A efficiencies.",
      "url": "https://finnhub.io/api/news?id=9036234003410c3dec310b1f6658396f9ccbd1362cb640fa63a2fc566734f6e5"
    }
  }
]